Quantatx

1 known investors

Quanta Therapeutics is developing orally bioavailable KRAS inhibitors for RAS-driven cancers, including candidates targeting KRASG12D, KRASG12V, and pan-KRAS mutations in pancreatic, colorectal, and endometrial cancers. The company uses conformational-sensitive assays to discover RAS-targeting therapeutics for oncology.

Biotech